Geriatric Intervention Contribution on Quality of Life of Elderly Patients With Metastatic Neoplasia

Terminated

• Conditions: Systemic Treatment; Elderly Patients; Metastatic Neoplasia
• Interventions: Other: geriatric intervention

• Registration Number: NCT03743961
• Lead Sponsor: Institut de Cancérologie de la Loire

Brief Summary

The aim of this study is to describe the impact of : Geriatric intervention contribution on quality of life of elderly patients receiving systemic treatments for metastatic neoplasia

Detailed Description

Elderly cancer incidence increases exponentially with advancing age. However, elderly patients are largely underrepresented in cancer treatment trials. The geriatric population presents particular physical, mental, psychological or social specificities that may condition the prognosis especially for patients with metastatic neoplasia. Recently, the measurement of quality of life (QoL) in aging population is being recognized as an important part of clinical decision. It is therefore essential to set up prospective studies to evaluate the impact of oncogeriatric practices on the quality of life of elderly patients with metastatic neoplasia. The main objective of this prospective study is to describe the contribution of geriatric intervention on quality of life for for elderly (\> 75 years) with metastatic solid cancer receiving systemic treatment during the first 6 months of their therapeutic management.

Study Timeline

• Study First Submitted: 2018-10-08
• Study First Submitted QC: 2018-11-15
• Study First Posted: 2018-11-16
• Study Start: 2018-11-21
• Status Verified: 2020-07
• Primary Completion: 2020-07-02
• Study Completion: 2020-07-02
• Last Update Submitted: 2020-07-03
• Last Update Posted: 2020-07-07

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

• Patient with solid metastatic neoplasia
• 75 years old or more
• Men or women
• ECOG between 0 and 3
• Patient receiving systemic antineoplasic treatment (chemotherapy, hormonotherapy, immunotherapy, targeted therapy)

Exclusion Criteria

• ECOG 4
• Localized cancer
• Patients already included in a study witch could modify quality of life
• Patient unable to give their consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Group B : geriatric intervention group	geriatric intervention	Evaluation of quality of life with the EORTC QoL ELD 14 (Quality Qf Life ELDerly patients) and QoL (Quality Qf Life) EORTC Q30 for patients with G8 score ≤14/17 ( in this arm there is two groups : patient who received geriatric intervention before treatment initiation (group A) and group of patient did not received geriatric intervention before treatment initiation( group B))

Primary Outcome Measures

Name	Time	Method
Level of quality of life	6 months	Level of quality of life will be measured with the QoL Q30 (Quality Qf Life with 30 Questions)

Secondary Outcome Measures

Name	Time	Method
Duration of hospitalizations	6 months	Duration of hospitalizations will be reported in hours
Number of toxicities ( grade 3 and 4)	6 months	Number of toxicities (grade 3 and 4) will be reported according to the CTCAE v4.0 (Common Terminology Criteria for Adverse Events)
number of hospitalizations	6 months	number of hospitalizations will be reported

Trial Locations

Locations (1)

Institut de Cancérologie Lucien Neuwirth; 🇫🇷 Saint-Priest-en-Jarez, France